Preliminary Experiences with Bio-Alcamid in HIV Facial Lipoatrophy
2007; Karger Publishers; Volume: 214; Issue: 2 Linguagem: Inglês
10.1159/000098575
ISSN1421-9832
AutoresYitzhack Ramon, Lucian Fodor, Yehuda Ullmann,
Tópico(s)Parvovirus B19 Infection Studies
Resumo<i>Background:</i> Highly active antiretroviral therapy for HIV-infected patients causes metabolic changes known as the lipodystrophy syndrome. Autologous fat injections, dermal fat grafts, malar implants and injected fillers have been reported as treatment options. <i>Objective:</i> To evaluate the results of HIV-infected patients treated with Bio-Alcamid for facial lipoatrophy. <i>Methods and Materials:</i> Over a 3-year period, 13 HIV-infected patients with facial lipoatrophy had Bio-Alcamid injections for aesthetic purposes. The procedure was done under local anesthesia, and the amount of the injected material varied from 5 to 13 ml. Results were independently evaluated by patients and physicians. <i>Results:</i> Most of the patients felt they had good to excellent results. Touch-ups were necessary for 2 patients; the added volume was 2–3 ml for each. No major complications were recorded. A small hematoma was noted in 1 patient. Overcorrection was attained in 2 cases, and some of the filler was removed at the patient’s request. <i>Conclusion:</i> One of the greatest advantages of this filler is that, although permanent, it can be removed easily. We consider Bio-Alcamid to be a safe and useful correcting tool for patients suffering from drug-induced facial lipoatrophy.
Referência(s)